1
|
Ben Ameur K, Chioukh FZ, Bouanene I, Ghedira ES, Ben Hamida H, Bizid M, Ben Salem K, Tabka R, Babba H, Monastiri K. [Evaluation of the measurement of capillary glucose concentration versus plasma glucose in the newborn]. Arch Pediatr 2016; 23:908-12. [PMID: 27369101 DOI: 10.1016/j.arcped.2016.04.025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2015] [Revised: 12/14/2015] [Accepted: 04/06/2016] [Indexed: 11/15/2022]
Abstract
BACKGROUND The reliability of blood glucose monitoring in neonatology is not always confirmed. The aim of this study was to evaluate the reliability of blood glucose measurements made with three different devices in newborns. PATIENTS AND METHODS The study was prospective, conducted in a medical and neonatal intensive care department over a period of 4 months. Capillary glucose level was measured with three different glucometers and compared with venous glucose level determined using the hexokinase method. An ANOVA and Scheffe test were used for the correlation analysis. RESULTS Three hundred and nine infants were included, with a mean age of 55h and a mean term of 39 weeks of gestation. Mean blood glucose in the laboratory was 0.62±0.15g/L, 0.71±0.17g/L for Accu-Chek(®) Active, 0.80±0.17g/L for Accu-Chek(®) Performa, and 0.83±0.12g/L for Bionime. An ANOVA showed statistically significant differences between the measurements made by glucometers compared to the reference blood glucose levels, and the Scheffé method showed that glucometers overestimated the real plasma glucose levels. CONCLUSION None of the devices used in this study was satisfactory. However, an estimation of blood glucose taking into consideration this numerical overestimation would allow early detection of hypoglycemia.
Collapse
Affiliation(s)
- K Ben Ameur
- Service de réanimation et de médecine néonatale, centre de maternité et de néonatalogie, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie; CHU Fattouma Bourguiba, Monastir, faculté de médecine de Monastir, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie.
| | - F Z Chioukh
- Service de réanimation et de médecine néonatale, centre de maternité et de néonatalogie, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie; CHU Fattouma Bourguiba, Monastir, faculté de médecine de Monastir, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie
| | - I Bouanene
- Service de médecine préventive et d'épidémiologie, centre de maternité et de néonatologie, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie; CHU Fattouma Bourguiba, Monastir, faculté de médecine de Monastir, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie
| | - E S Ghedira
- Laboratoire de biologie, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie
| | - H Ben Hamida
- Service de réanimation et de médecine néonatale, centre de maternité et de néonatalogie, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie; CHU Fattouma Bourguiba, Monastir, faculté de médecine de Monastir, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie
| | - M Bizid
- Service de réanimation et de médecine néonatale, centre de maternité et de néonatalogie, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie
| | - K Ben Salem
- Service de médecine préventive et d'épidémiologie, centre de maternité et de néonatologie, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie; CHU Fattouma Bourguiba, Monastir, faculté de médecine de Monastir, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie
| | - R Tabka
- Service de pharmacie hospitalière, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie
| | - H Babba
- Laboratoire de biologie, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie
| | - K Monastiri
- Service de réanimation et de médecine néonatale, centre de maternité et de néonatalogie, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie; CHU Fattouma Bourguiba, Monastir, faculté de médecine de Monastir, EPS Fattouma Bourguiba, 5000 Monastir, Tunisie
| |
Collapse
|
2
|
Aissa K, Kamoun F, Sfaihi L, Ghedira ES, Aloulou H, Kamoun T, Pissard S, Hachicha M. Hemolytic anemia and progressive neurologic impairment: think about triosephosphate isomerase deficiency. Fetal Pediatr Pathol 2014; 33:234-8. [PMID: 24840153 DOI: 10.3109/15513815.2014.915365] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We have reported the first Tunisian case of triosephosphate isomerase (TPI) deficiency in a 2-year-old girl. She was the first child of a nonconsanguineous couple. The disease included a neonatal onset of chronic hemolytic anemia, recurrent low-respiratory infections then progressive neurological involvement. The diagnosis was made after her death from the TPI values of her parents who exhibited intermediate enzyme deficiency. Molecular study of TPI genes showed that the father and the mother are heterozygous for Glu105Asp mutation. Pediatricians must be alert to the differential diagnosis in patients having hemolytic anemia and other concomitant manifestations.
Collapse
Affiliation(s)
- Khaoula Aissa
- 1Faculté de médecine de Tunis, Université Tunis Elmanar. Hôpital Mohamed Tlatli de Nabeul, pediatrics, Nabeul, Tunisia
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Ghedira ES, Lecerf L, Faubert E, Costes B, Moradkhani K, Bachir D, Galactéros F, Pissard S. Estimation of the difference in HbF expression due to loss of the 5' δ-globin BCL11A binding region. Haematologica 2012; 98:305-8. [PMID: 22801970 DOI: 10.3324/haematol.2012.061994] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
BCL11A was the focus of recent studies on its inhibiting effect when bound onto the β-globin cluster in the mechanism of hemoglobin switching and HbF downregulation. We examined a cohort of 10 patients displaying different HbF levels and short deletions within the γβ-δ intergenic region to find a possible correlation with the BCL11A binding site located 5' to the δ-globin gene. Precise characterization of deletions was achieved using a custom DNA-array chip and breakpoint sequencing. The α-globin cluster and major SNP associated with HbF expression were genotyped. Our results show that the loss of the BCL11A binding domain located 5' to the δ-globin gene is correlated with a strong HbF difference (mean+2.7 g/dL, ratio 2.81). This result provides evidence for the use of BCL11A level down-regulation or this domain blockage for new therapies in sickle cell disease and β-thalassemia major patients.
Collapse
Affiliation(s)
- Elyes Slim Ghedira
- APHP-Molecular Genetics Department, Henri Mondor Hospital, Créteil, France
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Ghedira ES, Dupin-Deguine D, Duffilot D, Lemetayer N, Faubert E, Pissard S. A Second Observation of the Rare Frameshift Mutation in the β-Globin Gene: Codon 46 (+A) (Hbb:c.138_139insA). Hemoglobin 2011; 35:157-61. [DOI: 10.3109/03630269.2011.557460] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|